A strong TPP helps define potency, clarify regulatory expectations, and align your entire development strategy.
For companies developing complex cell and gene therapies (CGT), every decision made early on—from dose design to potency assays—can have ripple effects through the entire development timeline. That’s why one of the most strategic tools a sponsor can implement, even in the preclinical phase, is the Target Product Profile (TPP).
But what exactly is a TPP, and why does it matter so much—especially in CGT?
At its core, the TPP is a planning document that outlines the desired characteristics of your product at the time of regulatory approval. It describes what the product is intended to do, for whom, and how it will be used. That includes everything from the indication, route of administration, and dosing frequency to safety expectations and clinical endpoints.
For CGT developers, the TPP goes even further—it informs how the product will be manufactured, tested, and controlled, from Phase I through licensure. It also lays the groundwork for regulatory interactions, such as pre-IND or scientific advice meetings.
For CGT developers navigating uncharted modalities and complex platforms, the TPP can serve as the anchor point for product decisions, helping to define potency strategies, streamline regulatory communication, and reduce the risk of development delays. Far from being a static document, the TPP acts as a strategic blueprint that connects clinical intent, quality targets, and regulatory expectations.
Why the TPP Is Critical in CGT Development
An effective TPP—and its regulatory CMC counterpart, the Quality Target Product Profile (QTPP)—helps shape some of the most fundamental product questions. It influences how potency is measured, what route and dosing are feasible, which quality attributes are considered critical, and how release specifications are determined. For advanced therapies where manufacturing scaling up and variability must be carefully controlled, the TPP becomes not just a scientific summary, but a development compass. Stability planning, shelf-life targets, and comparability strategies in the face of manufacturing changes all benefit from the foresight and structure that a well-crafted TPP provides.
Regulators increasingly recognize the importance of early alignment on potency and quality expectations. In its 2023 Draft Guidance on Potency Assurance, the FDA called for a lifecycle approach to potency strategy—one that adapts over time but starts with a solid foundation in the early stages. A thoughtfully designed QTPP, grounded in a clear understanding of the product’s mechanism of action, is central to this approach. It enables sponsors to identify potency-related critical quality attributes (CQAs) that not only support therapeutic claims but also inform the design of robust control strategies and lot release tests. These decisions have cascading impacts on assay development, CMC timelines, and ultimately, trial readiness.
Yet for many early-stage biotech companies—especially those with virtual teams or limited internal CMC expertise—building and maintaining a meaningful TPP can be challenging. It requires a coordinated understanding of regulatory trends, clinical endpoints, manufacturing feasibility, and analytical development.
When Should You Build a TPP?
The earlier, the better.
Ideally, your TPP should be drafted before your Pre-IND meeting. This allows you to align your development approach with regulators from the outset—and avoid costly rework later. For companies with lean teams or multiple outsourced partners (CDMOs, assay labs, consultants), having a clear TPP ensures everyone is working toward the same vision.
And because CGT development often evolves rapidly, your TPP should be treated as a living document—one that grows with your data, your understanding of the product, and your regulatory interactions.
Need help building or refining your TPP?
Ergomed brings together regulatory, clinical, and CMC expertise to support your early-stage CGT strategy—from development planning to global submission readiness. Whether you’re preparing for your first IND or scaling toward pivotal studies, we help ensure your TPP supports a smarter, faster, and more integrated development plan.